Mucus proteins that fail to achieve the correct structure cause airway secretions to become thick and sticky in patients with cystic fibrosis (CF), leading to the well-known symptoms of the disease, according to a study. The reason the proteins fail to assume the shape that’s seen in healthy people is simple,…
News
Rockefeller University researchers have mapped the three-dimensional structure of the protein involved in cystic fibrosis (CF). The mapping is important because knowing more about the CFTR protein will provide scientists with valuable insight into its activity and may lead to novel therapies for CF. Findings of the study, “Molecular…
Galapagos initiated a Phase 1 trial to evaluate its investigational drug GLPG3067 for cystic fibrosis (CF), triggering a $7.5 million milestone payment from AbbVie, its collaboration partner. Galapagos and AbbVie began a global collaboration in September 2013 to discover, develop and commercialize potentiator and corrector molecules for the…
Sound Pharmaceuticals has received a $1.6 million Cystic Fibrosis Foundation Therapeutics (CFFT) grant to test a therapy it has developed to improve hearing loss in cystic fibrosis (CF) patients being treated with tobramycin. Tobramycin is an antibiotic used to treat flare-ups in CF patients’ lung problems that are known as acute pulmonary exacerbations.
Kalydeco (ivacaftor, VX-770) improves bicarbonate secretion in cystic fibrosis (CF) patients with a certain gene mutation, according to a study. Bicarbonate is essential to digestion and the flow of several secretions in the body, including those of the intestine and pancreas. The report, “Impact of CFTR…
The activity of Zerbaxa (ceftolozane/tazobactam, or C/T) alone or in combination with other antibiotics shows promise against multi-drug resistant (MDR) Pseudomonas aeruginosa infection in pediatric cystic fibrosis (CF) patients, new research shows. The study, “In vitro Activity of Ceftolozane/Tazobactam Alone or with an Aminoglycoside Against Multi-Drug-Resistant Pseudomonas aeruginosa…
Cystic fibrosis (CF) patients have a poorer diversity of gut bacteria than healthy people, and it gets worse as the disease progresses, an Irish study indicates. In addition, patients with severe lung impairment have significantly fewer bacterial species in their gut than those with mild lung problems, researchers found. Because frequent intravenous antibiotic…
Aeolus Pharmaceuticals has released preliminary results from a study suggesting that AEOL 20415 could treat antibiotic-resistant bacteria, protecting the lungs in cystic fibrosis (CF). The company said its drug reduced infection, improved body weight and reduced the presence of white blood cells (macrophages and lymphocytes) in an animal model of CF. Brian Day, PhD,…
Canadians with cystic fibrosis (CF) live 10 years longer than Americans with the disease, a study shows. The life span of the average Canadian with CF was 50.9 years, versus 40.6 years for the average American, according to Anne Stephenson of St. Michael’s Hospital, the lead author of the study.
Using a virus may be a reliable way to treat antibiotic-resistant bacterial infections in cystic fibrosis (CF) patients’ lungs, according to a study. The approach is called phage therapy. Phage is a shortened version of bacteriophage, a virus that infects bacteria. The study, “Phage Therapy Is Highly Effective Against Chronic…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.